Hutchmed (China) Limited (HCM) ORD USD0.10
6.00p
(2.53%)
- Add to watchlist
- Create an alert
- This stock can be held in a
6.00p
(2.53%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
6.00p
(2.53%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
229.00p
236.00p
353.00p
£1.97 bn
237.00p
227.00p
187.50p
78.96
5.00p (2.16%) Previous:
5.00p
26,547
n/a
1,000
Performance
| 1 week 1W | 11.79% | 1 year 1Y | 19.93% |
|---|---|---|---|
| 1 month 1M | 1.72% | 2 years 2Y | 12.22% |
| 3 months 3M | 8.22% | 3 years 3Y | 8.93% |
| 6 months 6M | 24.76% | 5 years 5Y | 33.8% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
| Year ending: | 31/12/2024 | 31/12/2023 |
|---|---|---|
| Revenue ($m) | 630.20 | 838.00 |
| Profit before tax ($m) | (1.11) | 58.31 |
| Adjusted EPS (¢): | 4.00 | 12.00 |
| P/E ratio | 78.00 | 31.30 |
| PEG | n/a | n/a |
| EPS growth (%) | (67.00) | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Hutchmed enrols patients for phase two savolitinib trial
22 April 2025 08:46
-
Hutchmed renal cell carcinoma trial meets primary endpoint
19 March 2025 10:55
-
Hutchmed announces progress, hits milestone with lung cancer treatment
2 January 2025 15:30
-
HUTCHMED - Data to be Presented at AACR 2025
24 April 2025 07:00
-
HUTCHMED Completes Enrollment of Phase II Study
22 April 2025 07:00
-
2024 Annual Report and Notice of AGM
7 April 2025 09:30
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.